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Abstract Liposarcoma(LPS) is themost common type of soft
tissue sarcoma accounting for 20 % of all adult sarcomas.
However, the molecular pathogenesis of this malignancy is
still poorly understood. Here, we showed that GPS2 expres-
sion was downregulated in LPS and correlated with the prog-
nosis of this disease. In vitro study showed that knockdown of
GPS2 resulted in enhanced proliferation and migration of LPS
cell line SW872, without significant influence of cell death.
Conclusively, our results suggest that GPS2 may act as a tu-
mor suppressor in LPS and serve as a potential prognosis
marker for this disease.
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Introduction
Liposarcoma (LPS) is the most common subtype of soft tissue
sarcoma, accounting for 24 % of extremity and 45 % of retro-
peritoneal soft tissue sarcomas [1]. According to the World
Health Organization (WHO) classification guideline, LPSs
are divided to three subtypes: well-/dedifferentiated (WD/
DD) LPS, myxoid/round-cell (MRC) LPS, and pleomorphic
LPS (PLS) [2]. Among them, (WD/DD) histologies are the
most frequent types existed in 40–50 % of LPS cases [3].
WDLPS are low-grade tumors with a more indolent course,
while DDLPS are high-grade, aggressive tumors with a 15–
20% risk of distant metastasis and approximately 30% 5-year
survival rate [4]. Until now, surgery is the only curative ther-
apeutic strategy for localized disease, as these tumors are
largely resistant to conventional cytotoxic chemotherapy and
radiotherapy as well [5, 6]. However, there are still 58 to 80 %
of patients with DDLPS of the retroperitoneum will succumb
to locally recurrence or metastasis within 5 years [7]. Thus, it
is of great urgency to develop effective targeted therapies to
improve outcomes of patients with liposarcoma. Nevertheless,
it has been hampered by a lack of understanding of the path-
ogenesis of this disease.
In the past decade, new approaches, including gene expres-
sion profiling, DNA copy number profiling, whole-exome
sequencing, miRNA profiling, and RNA sequencing, have
successfully used to expand our understanding of LPS patho-
genesis [7–10]. Amplification of chromosome 12q14-15 was
the best-studied molecular aberration in LPS, which results in
amplification of the MDM2 (located at 12q15) and CDK4
gene in over 90 % of WD/DD LPS cases [11–14]. This am-
plification was reported to cause decreased apoptosis and in-
creased cell proliferation, which were thought to be resulted
from dysregulation of the p53 pathway and the Rb-E2F cell
cycle checkpoint [4, 14]. Multiple mechanisms including ge-
netic amplifications, overexpressions of receptor tyrosine ki-
nases (RTKs), chromosome translocation, deregulation of
PI3K/Akt pathway, dysregulation of some miRNAs, and de-
regulation of epigenetics are reported to be associated with the
development of LPS [4].
G protein pathway suppressor 2 (GPS2), located at
17p13.1, was originally identified as a suppressor of Ras
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activation in the yeast [15]. It was later shown to be involved
in many physiological and pathological processes, including
proliferation, apoptosis, DNA repair, brain development, and
metabolism [16–20]. Dysregulation of GPS2 has been report-
ed to be associated with tumorgenesis of glioblastoma
multiforme and undifferentiated spindle cell sarcoma (UDS)
[21]. However, the role of GPS2 in tumorgenesis remains
largely unknown.
In view of that GPS2 is downregulated in the adipose tissue
of obese individuals and that it plays a critical role in the
regulation of adipose tissues [22], we attempt to explore the
potential role of GPS2 in LPS, the most common subtypes of
soft tissue sarcoma.Our results indicated that GPS2 act as a tumor




The human SW872 cell line was obtained from the
Department of Public Health of Harbin Medical University.
The cells were grown in DMEM supplemented with 10 %
FBS, penicillin (100 U/ml), at 37 °C in 5 % CO2.
Lentivirus transduction
The pSicoR-GFP vectors carrying the GPS2-shRNA-1 se-
quence GAGGAGACCAAGGAACAAA or GPS2-shRNA-
2 sequence GGAAGAGAGAATGTCATTA were used as in
this study. The lentiviruses were packaged by cotransfected
lentivirus vector with psPAX2 and pMD2.G into 293T cells.
The gene transduction efficiency of lentiviral vectors, indicat-
ed by GFP expression, was detected by flow cytometry
(Becton Dickinson, Mountain View, CA). SW872 cells were
plated in six-well plate at a density of 2 × 105 per well, and
then were infected by lentiviral vectors at multiplicity of in-
fection (MOI) of 10.
Wound-healing and migration assays
To analyze wound-healing ability of SW872 cells, 2 × 105
cells were seeded in six-well plates with DMEM supplement-
ed with 10% FBS. After 24 h, the cell monolayer was wound-
ed using a plastic pipette tip. The cells were then rinsed with
PBS and cultured with serum-free DMEM for 24 h. The
wound closure was observed and photographed under a
microscope.
The migration assay was performed using Transwell inserts
(Costar, NY, USA; pore size, 8.0 μm) in 24-well cell plates.
SW872 cells transduced with 10 MOI lentivirus for 48 h was
assayed. Approximately 1 × 105 cells in 100 μl serum-free
medium were placed in the upper chamber, and 600 μl of
the same medium containing 10 % FBS was placed in the
lower chamber. The plates were incubated for 5 h at 37 °C
in 5 % CO2; then, cells were washed with 600 μl PBS for
twice and fixed in 2 % paraformaldehyde for 20 min. After
that, nonmigrating cells in the upper chambers were removed
with a cotton swab; migrated cells on the lower surface of the
porous membrane were remained. Migrated cells were stained
with crystal violet for 10 min and photographed under an
optical microscope. Five random fields (×100) were chosen
in each well, and the cell number was quantified manually.
The average number of migrated cells of five fields was com-
pared among two groups.
RNA extraction and quantitative RT-PCR
Total RNAwas extracted with TRIzol reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA), and cDNA was synthe-
sized using Revert Aid™ First Strand cDNA Synthesis Kit
(Thermo Scientific, Wilmington, DE) according to the techni-
cal manual. The mRNA expression of target genes was quan-
tified using 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA) and SYBR® Premix Ex Taq™
II (Takara, Japan). Their expression levels were normalized by
β-actin. The PCR primers were designed and synthesized in
AUGCT Biological Technology Co., Ltd., Beijing, China.
The primers are listed in Table 1.
Protein extraction and Western blot
Cells were washed twice with 1× PBS, and protein was ex-
tracted from SW872 transduced with lentivirus. Total cell pro-
tein concentrations were confirmed using BCA protein assay
kit. Then, 40 μg of the sample was separated by sodium
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dodecylsulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to PVDF membranes. After blocking
with 5 % nonfat milk in Tris-buffered saline containing 0.1 %
Tween 20 (TBST), the membranes were incubated at room
temperature for 5 h with primary antibody (mouse anti-
GPS2 (1:1000 dilution, made by our lab); mouse anti-
GAPDH (1:1000 dilution, ASGB-BIO, China); mouse anti-
Cyclin D1 (1:1000 dilution, CST, USA), mouse anti-PPARγ
(1:1000 dilution, CST, USA)). The membranes were then
washed three times with TBSTand incubated with the second-
ary antibody at room temperature for 50 min in 5 % milk in
TBST. After five washes with TBST, the membranes were
visualized with enhanced chemiluminescence detection kit
(ECL, Amersham Pharmacia). GAPDH functioned as an in-
ternal control. Tanon 5200 imaging system (Tanon Company
Ltd., Shanghai, China) was used to acquire the blots.
DYE670 staining assay
The GPS2-shRNA and ctrl-shRNA transduced cells were
washed two times with PBS to remove serum, then resuspend-
ed at 1.0 × 106/ml in PBS (prewarmed to room temperature).
The cell suspension was mixed with a solution of Cell
Proliferation Dye eFluor® 670 and incubated for 10 min at
37 °C in the dark, then labeling was stopped by adding 4–5
volumes of cold complete media (containing 10% serum) and
incubated on ice for 5 min. After washed for three times with
complete media, the cells were cultured at 5 % serum medium
at 37 °C in 5 % CO2 for 0, 48, 72, and 96 h, respectively.
These cells were collected and fixed in 2 % paraformaldehyde
at 4 °C for flow cytometry assay. Flow cytometric analysis
was conducted on a FACSCalibur can using the Cell Quest
software package (Becton Dickinson, CA).
BrdU staining assay
For the BrdU assay, cells were seeded in six-well plates and
cultured in DMEM supplemented with 10 % FBS or control
media for 24 h and then 10 μMBrdU (BrdU assay kit, Kai Ji,
Nanjing, China) was added. After 8 h, cells were rinsed twice
with PBS and then were incubated in working liquid at 37 °C
for 30 min. At last, cells were suspended in 200 μl of staining
buffer with 5 μl of a PE-BrdU antibody for 30 min at 4 °C
without light and were imaged by an IX70 inverted micro-
scope (Olympus, Hamburg, Germany). Experiments were
performed in triplicate and tracks of at least ten cells from
three positions were analyzed in each well for different
conditions.
Apoptosis assays
Annexin V/phosphoinositide (PI) apoptosis detection kit was
used to detect externalization of phosphatidylserine according
to the manufacturer’s instructions (BD Pharmingen). In brief,
1 × 106 SW872 cells were washed twice with PBS and stained
with 5 μl of Annexin V-FITC for 15 min and 10 μl of PI in
binding buffer (10 mM Hepes, pH 7.4, 140 mM NaOH, and
2.5 mM CaCl2) for 15 min at 4 °C. Flow cytometric analysis
was conducted on a FACSCalibur using the Cell Quest soft-
ware package (Becton Dickinson). Apoptotic cells were de-
fined as Annexin V+/PI−.
Cell cycle analysis
For flow cytometry measurements of the cell cycle, 48-h
posttransfection cells were collected, centrifuged at 300×g
for 5 min, and fixed overnight in 70 % cold ethanol at
−20 °C. After washing twice with PBS, the cells were resus-
pended in 500 μl of fresh PBS containing 50 μl of 2 mg/ml
RNaseA and 10 μl of 1 mg/mL PI (Sigma). Cells were incu-
bated for 15 min at 37 °C. The cells were then analyzed im-
mediately using a FACSCalibur using the Modfit software
(Becton Dickinson) at 30,000 events/sample.
Glucose concentration test
The concentrations of glucose in culture medium were deter-
mined by the glucose oxidase method in North of Beijing
Institute of Biotechnology Co., Ltd.
Tumor and normal tissue samples
For the human tissue samples, a total of 50 fresh tumor sam-
ples and corresponding normal samples were obtained from
patients in the Chinese PLA General Hospital during surgery.
Clinical data about 50 patients with retroperitoneal
liposarcoma managed with surgery in our hospital from
January 2003 to December 2014 were retrospectively ana-
lyzed, and all patients were followed up. Informed consent
was obtained from all patients prior to tissue collection. No
Table 2 The clinicopathological information of LPS patients
Characteristics Value
Age
Mean ± SD 51.79167 ± 12.7824 years
Range 26–85 years
Gender
Male 28 (56 %)
Female 22 (44 %)
Histologic subtype
WD 27 (54 %)
DD 23 (46 %)
Median follow-up 28 months
Tumor Biol. (2016) 37:13333–13343 13335





bFig. 1 GPS2 expression in LPS.
a Relative GPS2 expression in 14
LPS samples and their paired
normal adipose tissues. bRelative
GPS2 expression in WDLPS and
DDLPS in the LPS samples. c
IHC staining of CDK4, MDM2,
and GPS2 proteins in WDLPS
and DDLPS. H&E staining
(×200) shows the morphologic
characters of four cases of
WDLPS and DDLPS. IHC
staining of CDK4, MDM2, and
GPS2 protein showed variable
expression patterns of WDLPS
and DDLPS. d The heat map of
immunohistochemistry staining
results of CDK4, MDM2, and
GPS2 in samples from LPS
patients. e Kaplan–Meier survival
analysis showed the different
prognosis of different expression
of GPS2. Data for gene copy
number are presented as ratio to
β-actin. Significance, **P
values < 0.01
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patients had received radiation therapy or chemotherapy prior
to surgery. The clinicopathological information of patients,
including age, gender, histological type, and median follow-
up was obtained from patient records and is summarized in
Table 2.
Immunohistochemistry
Commercially available monoclonal antibodies against CDK4
(Clone DCS-31, 1:50, Invitrogen), MDM2 (Clone IF-2,1:75,
Zymed Laboratories), and GPS2 (1:100)were used. Anti-
GPS2 antibodies for Western blotting were made by our lab
(1:100). All WDLPS and DDLPS cases were stained for
CDK4, MDM2, and GPS2 by immunohistochemistry.
Sections were deparaffinized and rehydrated in graded alco-
hol. For heat-induced epitoperetrieval (HIER), the sections
were subjected to DIVA retrieval buffer (pH 6.0) in a pressure
cooker (Biocare Medical) at 98 °C for 60 min. The sections
were then brought to an automated stainer (DAKO) following
the vendor’s protocol. EnVisionPlus and peroxidase detection
methods were used and counterstained in 50 % Mayer’s he-
matoxylin for 1 min. Nuclear CDK4 immunoreactivity, nucle-
ar and cytoplasmicMDM2 immunoreactivity, and nuclear
GPS2 immunoreactivity were assessed. Those cases with
more than 1 % of tumor cells showing positive staining were
assessed as positive. The staining was graded as + (1–5 %
tumor cells positive),++ (5–24 % tumor cells positive), and
+++ (>25% tumor cells positive). The immunohistochemistry
staining results of patients were shown as heat maps.
Adipogenic differentiation
The cells were cultured in adipogenic differentiation media
(Lonza, USA)for 9 days. Adipogenic differentiation was char-
acterized with Oil Red O staining. The cells were fixed in 4 %
paraformaldehyde, washed, and treated with 60 % ethanol for
5 min. Oil Red O stain was added for 10 min, and cells were
imaged for fat droplet formation using the Olympus micro-
scope (Hamburg, Germany).
Statistical analysis
All results are representative of three independent experi-
ments. Values were presented as mean ± SD. All data were
analyzed by using SPSS19.0 and GraphPad Prism 5.
Differences between the experimental groups and control
groups were assessed by the Student’s t test (two-tailed).
The results of immunohistochemistry were analyzed by
Mann–Whitney test. The Kaplan–Meier method was used to
describe and evaluate the survival rate, and the log-rank test
was used to compare the survival curves. Data with P < 0.05
were considered statistically significant.
Results
GPS2 expression and its correlation to prognosis of LPS
To explore the potential role of GPS2 in liposarcomas, we
collected 14 LPS samples and their paired normal adipose
tissues. qPCR analysis showed that the mRNA levels of
GPS2 were significantly lower in tumor samples than
their normal control (Fig. 1a). Further clinicopathologic
analysis revealed that those samples containing seven
WDLPS, five DDLPS, and two other subtypes of LPS.
We next compared the GPS2 expression in WD and DD
LPS. GPS2 mRNA levels were lower in DDLPS than that
in WDLPS (Fig. 1b). To further confirm these results, we
collected 50 samples with 27 WDLPS and 23 DDLPS.
Immunohistochemical analysis showed that 74.07 % of
WDLPS were GPS2 positive whereas only 52.17 % of
DDLPS were GPS2 positive (Fig. 1c, d). We analyzed
Table 3 The
immunohistochemistry staining
results of samples from LPS
patients
Items Percentage CDK4 MDM2 GPS2
DD (n = 23) − 8.70 % (2/23) 13.04 % (3/23) 47.83 % (11/23)
+ 26.09 % (6/23) 30.43 % (7/23) 26.09 % (6/23)
++ 30.43 % (7/23) 26.09 % (6/23) 17.39 % (4/23)
+++ 34.78 % (8/23) 30.43 % (7/23) 8.70 % (2/23)
Sum of positive 91.30 % (21/23) 86.96 % (20/23) 52.17 % (12/23)
WD (n = 27) − 29.63 % (8/27) 33.33 % (9/27) 25.93 % (7/27)
+ 37.04 % (10/27) 37.04 % (10/27) 22.22 % (6/27)
++ 18.52 % (5/27) 18.52 % (5/27) 22.22 % (6/27)
+++ 14.81 % (4/27) 11.11 % (3/27) 29.63 % (8/27)
Sum of positive 70.37 % (19/27) 66.67 % (18/27) 74.07 % (20/27)
Total positive 80.00 % (40/50) 76.00 % (38/50) 64.00 % (32/50)
P 0.015 0.015 0.025
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the MDM2 and CDK4 expression synchronously. In ac-
cordance with previous reports, MDM2 was positive in
76.00 % cases and the percentage of CDK4 positive was
80.00 % (Fig. 1c, d). The preventative photographs were
exhibited as Fig. 1c. Collectively, these results suggested
that GPS2 expression was downregulated in LPS and es-
pecially in high-grade tumors, implicating GPS2 may has
a role in the genesis of these tumors.
It is suggested that GPS2 downregualtion may associ-
ate with the malignant degrees of LPS. This assumption
conducted us to examine the correlation of GPS2 expres-
sion levels to predict clinical outcomes. Twenty-three pa-
tients with DDLPS and 27 individuals with WDLPS were
enrolled in this prospective study. The general information
of these patients is listed in Table 2. Kaplan–Meier sur-
vival analysis showed that patients whose tumors had
lower GPS2 expression levels had a worse prognosis
(Fig. 1e). These data indicated GPS2 may serve as a prog-
nosis marker of these diseases (Table 3).
Enhanced proliferation in GPS2 knocked-down SW872
cells
To explore the roles of GPS2 in regulation of biological char-
acteristics of liposarcoma cells, we checked the effect of loss
of GPS2 on proliferation, migration, and apoptosis of SW872
cells in vitro. GPS2 knockdown cell line was established by
transfecting SW872 cells with GPS2-shRNA. qPCR and
Western blot analysis confirmed the knockdown efficacy of
both GPS2-shRNA1 and GPS2-shRNA2 (Fig. 2a, b).
Proliferation index showed that transduction of both GPS2-
shRNA1 and GPS2-shRNA2 leads to enhanced proliferation
of SW872 cells (Fig. 2c, d). This is further confirmed by a
BrdU staining assay (Fig. 2e). In concert, elevated glucose
consumption was observed in GPS2 knocked-down cell cul-
tures in contrast to the control cells (Fig. 2f). These results
suggested that GPS2 may act as a negative regulator of cell
proliferation in vitro.
GPS2 knockdown promoted cell cycle progression
with few influences on apoptosis of SW872 cells
In previous results, we showed that GPS2 knockdown resulted
in enhanced proliferation of SW872 cells. As the increase of
cell numbers could be either attributed to more cell divisions,
less cell death, or both, we assessed the influences of GPS2
knockdown on cell cycle progression and apoptosis. Flow
cytometry analysis showed that GPS2 knockdown induced
more cells into cell cycles, revealed by increased percentages
in S phase and G2/M phase (Fig. 3a, b). But the Annexin V-
positive cells were comparable in GPS2 knockdown cells and
control cells (Fig. 3c, d), suggesting few influences of GPS2
on cell death. Cyclin D is a member of the cyclin protein
family that is involved in regulating cell cycle progression.
The synthesis of cyclin D is initiated during G1 and drives
the G1/S phase transition. We further validated that cyclin D1
was increased in GPS2 knockdown cells. Meanwhile, the ad-
ipose differentiation maker PPARγ was downregulated
(Fig. 3e). These results suggested that GPS2 could promote
cell differentiation and inhibit cell division, but had few im-
pacts on cell death.
GPS2 knockdown enhances migration of SW872 cells
To validate whether GPS2 regulated cell migration, wound-
healing and trans-well assays were performed. The abilities of
migration were increased in GPS2 knockdown SW872 cells,
in contrast to the control cells (Fig. 4a, b). These results indi-
cated that loss of GPS2 leads to more aggressive phenotypes
of SW872 cells. The increased abilities of migration were
commonly associated with dedifferentiation, a histologic form
of tumor progression, which was also described as epithelial
mesenchymal transition (EMT) in its extreme form [23, 24].
GPS2 knockdown also suppressed adipogenic differentiation
in SW872 cell line (Fig. 4c). Since GPS2 has been reported to
regulate the activities of peroxisome proliferator-activator re-
ceptor (PPARγ), the master regulator of adipocyte differenti-
ation [25–27], we checked whether loss of GPS2 resulted in
dedifferentiation. As expected, adipose differentiation makers
including LPL, Pref1, C/EBP, PPARγ1, and PPARγ2 were
decreased in GPS2 knockdown cells than that in control cells
(Fig. 4d).
Discussion
LPS are a group of soft tissue sarcomas with great diversity
and low prevalence. Gaining a better understanding of the
pathogenesis of these diseases is the first step toward the de-
velopment of effective targeted therapies to improve outcomes
in patients with this disease. However, the molecular patho-
genesis of these malignancies are still poorly understood. In
Fig. 2 GPS2 knockdown enhances proliferation of SW872 cells. a
SW872 cells transfected with sh-ctrl, GPS2-sh1, and GPS2-sh2 were
subjected to q-PCR analysis. GPS2 mRNA levels were normalized to
β-actin. b GPS2 protein levels were determined by Western blot,
GAPDH as a loading control. c SW872 cells transfected with sh-ctrl,
GPS2-sh1, and GPS2-sh2 were labeled with Dye670 and cultured for
4 days. Cell division was evaluated on the basis of reduction of Dye670
fluorescence intensity. A proliferation index (PI) was calculated using
ModFit software. d The representative plot of Dye670-labeled cells for
proliferation index assay. e The cells infected with sh-ctrl or GPS2-sh1
were photographed using BrdU staining. f Glucose concentrations in the
medium of cells infected with sh-ctrl or GPS2-sh1 were detected from
day 0 to day 4. Cumulative results represent the mean ± SEM.
Significance, **P < 0.01
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this study, we reported that GPS2, a small transactional cofac-
tor, functioned as a tumor suppressor in LPS. More important-
ly, our data suggested that GPS2 levels were correlated to the
prognosis of this disease.
GPS has been shown to regulate suppress G-protein- and
RAS- mitogen-activated protein kinase-mediated signal trans-
duction which are required for cell proliferation and migration








Fig. 3 Effects of GPS2 on cell-cycle progression and apoptosis of
SW872 cells. a, b The cells infected with sh-ctrl and GPS2-sh1 were
stained with PI, and DNA content was analyzed by flow cytometry.
The cell cycle distribution was calculated using ModFit software. a The
representative plot of DNA content using flow cytometry. b The
percentage of cell cycle distribution of SW872 cells infected with sh-
ctrl or GPS2-sh1 vector. c, d The SW872 cells transfected with sh-ctrl
or GPS2-sh1 vector were in serum-starved culture for 24 or 48 h.
Apoptosis was detected by Annexin V-FITC/PI staining. c The
representative plot of apoptosis assay using flow cytometry. d The
percentage of apoptotic cells. e SW872 cells were transfected with sh-
ctrl, GPS2-sh1, and GPS2-sh2 vector. The PPARγ and cyclin D1 protein
levels were determined by Western blot, GAPDH as a loading control
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transduction, we identified that GPS2 silence resulted in en-
hanced proliferation and migration in SW872 cells in vitro.
These data suggested that GPS2 functioned as a tumor sup-
pressor in LPS. Furthermore, we also identified that GPS2
knockdown caused dedifferentiation of these cells. To our
knowledge, this is the first report focusing on the biological
functions and significance of GPS2 in these malignancies.
However, studies with large sample size are still needed to
further confirm the importance of GPS2 in LPS.
Besides the genetic amplification of the 12q13-15, other
molecular mechanisms of LPS genesis have been proposed





Fig. 4 GPS2 knockdown
enhances migration and reduces
differentiation of SW872 cells. a,
b The SW872 cells transfected
with GPS2-sh1 or control vector
were evaluated for abilities of
migration by using wound-
healing assay (the right chart
shows the percentage of healing
areas) (a) and transwell assay( the
right chart shows the number of
migrated cells ) (b). The
phenotype experiment showed
the ability of adipogenic
differentiation after the
knockdown of GPS2 ( the right
chart shows the percentage of
differentiated cells) (c). The
expression of adipogenic
markers, LDL, Pref1, C/EBPα,
PPARγ1, and PPARγ2, were
determined by Q-PCR in SW872
cells transfected with sh-ctrl,
GPS2-sh1, and GPS2-sh2 (d)
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their downstream targets, epigenetics, and dysregulation of
some oncogenic signaling pathways [4, 10, 28–31].
Particularly, amplification of the oncogene C-JUN is consid-
ered to contribute to the inhibition of PPARγ, a key regulator
in terminal adipocyte differentiation [32]. In view of that LPS
growth was inhibited by downregulating C-JUN via
deoxyribozyme (DNAzyme) and that GPS2 was demonstrat-
ed to suppress JNK signaling [33], we reasoned that GPS2
may regulate LPS growth and migration through JNK1-
PPARγ pathway. This hypothesis will be verified in future
studies.
GPS2, first identified as a suppressor of Ras activation, was
later shown to be involved in many physiological and patho-
logical processes, including proliferation, apoptosis, DNA re-
pair, brain development, and metabolism [16–20]. The role of
GPS2 in adipose differentiation and lipid metabolism has been
intensively studied. Toubal et al. reported that SMRT-GPS2
corepressor pathway dysregulation coincides with obesity-
linked adipocyte inflammation [22]. GPS2 has been also re-
ported to be required for cholesterol efflux [34]. Together, this
body of work implicates that GPS2 was a critical regulator of
adipose tissues. However, the role of GPS2 in adipose
origined tumors has not been unveiled. The present studies
expanded our understanding of the function of GPS2 and
highlight the importance of GPS2 in tumorgenesis of soft
tissue sarcomas.
In conclusion, our studies identify GPS2 functions as a
tumor suppressor in LPS and its downregulation is correlated
to prognosis of LPS. These studies enhance our understanding
the molecular pathogenesis of LPS and raise the possibility
that GPS2 served as a potential prognosis marker.
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